Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 8/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17479006 | 0.91 | SMN1; SMN2 (0.43) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479795 | 0.91 | SMN1; SMN2 (0.45) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479172 | 0.90 | SMN1; SMN2 (0.42) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479698 | 0.89 | SMN1; SMN2 (0.44) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479057 | 0.86 | PARP3 (0.46) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479697 | 0.81 | MAPK1 (0.38) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479705 | 0.80 | HSD17B10 (0.42) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479741 | 0.79 | KDM4E (0.38) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479797 | 0.74 | MEN1 (0.53) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 | |
| SCHEMBL17479324 | 0.72 | TSHR (0.38) | KDM4ESMN1; SMN2HPGDHSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | claimed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | claimed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | claimed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | claimed |
| CN-107001283-B | FLT3 receptor antagonists | 国家健康与医学研究院 | 2021-05-25 | — | — | CN | disclosed |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-06-04 | — | — | US | disclosed |
| CN-111093640-A | FLT3 inhibitors for improving opioid pain therapy | 国家健康与医学研究院 | 2020-05-01 | — | — | CN | disclosed |
| EP-3174859-B1 | FLT3 RECEPTOR ANTAGONISTS | INST NAT SANTE RECH MED (FR) | 2020-04-29 | — | — | EP | disclosed |
| EP-3624780-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018211018-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-11-22 | — | — | WO | disclosed |
| US-10065937-B2 | FLT3 receptor antagonists | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-09-04 | — | — | US | disclosed |
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-08-17 | — | — | US | disclosed |
| EP-3174859-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016016370-A1 | FLT3 RECEPTOR ANTAGONISTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233354-A1 | FLT3 RECEPTOR ANTAGONISTS | FLT3, CSF1R, CSF3R | KDM4E 2965/4885SMN1; SMN2 3517/4885HPGD 3601/4885 |
| US-10065937-B2 | FLT3 receptor antagonists | FLT3, CSF1R, CSF3R | KDM4E 2965/4885SMN1; SMN2 3517/4885HPGD 3601/4885 |
| US-20200171022-A1 | FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS | FLT3, CSF1R, OPRL1 | KDM4E 362/4885SMN1; SMN2 3037/4885HPGD 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.